[{"id":"dc5b63d1-d71c-461a-9555-93d27bcb4d1c","acronym":"PRO00041908","url":"https://clinicaltrials.gov/study/NCT05038644","created_at":"2021-09-09T13:53:03.633Z","updated_at":"2024-07-02T16:35:11.572Z","phase":"Phase 1","brief_title":"XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia","source_id_and_acronym":"NCT05038644 - PRO00041908","lead_sponsor":"Ehab L Atallah","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e XmAb968"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/02/2022","start_date":" 02/02/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-04-03"},{"id":"6b3f889b-f740-4f3b-8cf4-23be6228dabd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04684108","created_at":"2021-01-19T20:47:15.713Z","updated_at":"2024-07-02T16:35:12.449Z","phase":"Phase 1","brief_title":"SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies","source_id_and_acronym":"NCT04684108","lead_sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SG301 IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-28"},{"id":"7158f3c8-048e-44f4-84c4-9fea0fbb9783","acronym":"","url":"https://clinicaltrials.gov/study/NCT06282978","created_at":"2024-02-29T03:33:45.743Z","updated_at":"2024-07-02T16:35:16.129Z","phase":"Phase 2","brief_title":"Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes","source_id_and_acronym":"NCT06282978","lead_sponsor":"PETHEMA Foundation","biomarkers":" KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81","pipe":" | ","alterations":" CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression","tags":["KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elrexfio (elranatamab-bcmm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/23/2023","start_date":" 11/23/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-03-06"},{"id":"67a15808-0681-4add-b990-145069d8cdb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04714372","created_at":"2021-01-19T20:53:07.373Z","updated_at":"2024-07-02T16:35:23.907Z","phase":"Phase 1","brief_title":"FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia","source_id_and_acronym":"NCT04714372","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • IDH1 • IDH2 • CD38","pipe":" | ","alterations":" CD38 expression","tags":["FLT3 • IDH1 • IDH2 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT538 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 01/09/2024","primary_completion_date":" 01/09/2024","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2024-01-10"},{"id":"3c4991de-db64-4065-98be-20d6b4e3f446","acronym":"","url":"https://clinicaltrials.gov/study/NCT03848676","created_at":"2021-01-18T18:59:48.511Z","updated_at":"2024-07-02T16:35:36.215Z","phase":"","brief_title":"Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma","source_id_and_acronym":"NCT03848676","lead_sponsor":"University of Turin, Italy","biomarkers":" CD8 • IL6 • CD38 • CRBN • DKK1 • CD4 • CD55 • CD59","pipe":" | ","alterations":" CD38 expression • CRBN mutation","tags":["CD8 • IL6 • CD38 • CRBN • DKK1 • CD4 • CD55 • CD59"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CRBN mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-09-21"},{"id":"8d47bbb6-06cc-480c-98ad-8a291714a09d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05442580","created_at":"2022-07-05T14:54:23.025Z","updated_at":"2024-07-02T16:35:45.090Z","phase":"Phase 1","brief_title":"CART-38 in Adult AML and MM Patients","source_id_and_acronym":"NCT05442580","lead_sponsor":"University of Pennsylvania","biomarkers":" CD38 • CD34","pipe":" | ","alterations":" CD38 expression","tags":["CD38 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CART-38"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 05/01/2041","primary_completion_date":" 05/01/2041","study_txt":" Completion: 05/01/2041","study_completion_date":" 05/01/2041","last_update_posted":"2023-06-22"},{"id":"1a20e268-2930-4294-b911-885f239ea93c","acronym":"DILEMMA","url":"https://clinicaltrials.gov/study/NCT05835726","created_at":"2023-04-28T15:04:55.549Z","updated_at":"2024-07-02T16:35:49.208Z","phase":"","brief_title":"Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.","source_id_and_acronym":"NCT05835726 - DILEMMA","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" CD38 • CD34","pipe":" | ","alterations":" CD38 expression","tags":["CD38 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Darzalex (daratumumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 188","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-05-01"},{"id":"2add9cbf-45b6-4ca2-b88c-b9bfd4516d3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05007418","created_at":"2021-08-16T16:54:44.805Z","updated_at":"2024-07-02T16:35:57.559Z","phase":"Phase 1b","brief_title":"Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT05007418","lead_sponsor":"Sorrento Therapeutics, Inc.","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STI-1492"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-01-16"},{"id":"b1d5a974-0b04-421b-8acb-a796d504456e","acronym":"IDA53","url":"https://clinicaltrials.gov/study/NCT03734198","created_at":"2021-01-18T18:17:21.383Z","updated_at":"2024-07-02T16:36:08.182Z","phase":"Phase 2","brief_title":"Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction","source_id_and_acronym":"NCT03734198 - IDA53","lead_sponsor":"French Innovative Leukemia Organisation","biomarkers":" TP53 • CD38","pipe":" | ","alterations":" TP53 mutation • CD38 expression","tags":["TP53 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Darzalex (daratumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/19/2018","start_date":" 12/19/2018","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2022-06-28"},{"id":"5f58e372-e1e5-4755-993d-8ec12f5756c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT00741455","created_at":"2021-01-18T02:48:01.529Z","updated_at":"2024-07-02T16:36:38.285Z","phase":"","brief_title":"Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT00741455","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" CD38","pipe":" | ","alterations":" CD38 expression","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclosporine • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2004","start_date":" 06/01/2004","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2020-11-23"},{"id":"591f8526-ce03-4da2-985b-c4d42f183ed9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04000698","created_at":"2021-01-18T19:39:51.048Z","updated_at":"2024-07-02T16:36:38.415Z","phase":"Phase 3","brief_title":"Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias","source_id_and_acronym":"NCT04000698","lead_sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","biomarkers":" BCL2 • CXCR4 • CD38","pipe":" | ","alterations":" CD38 expression • BCL2 expression","tags":["BCL2 • CXCR4 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • Actemra IV (tocilizumab) • Grafapex (treosulfan) • Orencia (abatacept)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/15/2019","start_date":" 10/15/2019","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-11-20"},{"id":"dc88e68f-f782-4d5a-b32b-216a22465e77","acronym":"","url":"https://clinicaltrials.gov/study/NCT01269385","created_at":"2021-01-18T05:07:58.484Z","updated_at":"2024-07-02T16:36:43.905Z","phase":"Phase 1/2","brief_title":"Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT01269385","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • IGH • CD38 • CD5 • FCER2","pipe":" | ","alterations":" CD38 expression • CD20 expression","tags":["CD20 • CCND1 • IGH • CD38 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Campath (alemtuzumab) • Imprime PGG (odetiglucan)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 06/01/2014","primary_completion_date":" 06/01/2014","study_txt":" Completion: 06/01/2015","study_completion_date":" 06/01/2015","last_update_posted":"2020-06-23"},{"id":"f5f7e9e9-4884-4e93-8627-a995d1f87bfb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00562328","created_at":"2021-01-18T02:02:58.656Z","updated_at":"2024-07-02T16:36:46.382Z","phase":"Phase 2","brief_title":"Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT00562328","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD38 • CD5 • FCER2","pipe":" | ","alterations":" CD19 positive • CD38 expression • CD20 expression • CD5 positive","tags":["CD20 • CCND1 • CD38 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD38 expression • CD20 expression • CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Campath (alemtuzumab) • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 02/05/2010","primary_completion_date":" 02/05/2010","study_txt":" Completion: 12/18/2014","study_completion_date":" 12/18/2014","last_update_posted":"2020-04-08"},{"id":"fe92fdc8-a6cc-4f7e-b693-b575fed6d7de","acronym":"","url":"https://clinicaltrials.gov/study/NCT01118234","created_at":"2021-01-18T04:26:04.369Z","updated_at":"2024-07-02T16:36:51.546Z","phase":"Phase 3","brief_title":"Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)","source_id_and_acronym":"NCT01118234","lead_sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","biomarkers":" CD38","pipe":" | ","alterations":" Chr del(11q) • CD38 expression • TS 12","tags":["CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(11q) • CD38 expression • TS 12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab)"],"overall_status":"Completed","enrollment":" Enrollment 256","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 02/01/2018","primary_completion_date":" 02/01/2018","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2020-01-09"}]